Coactivation of 𝛍- and 𝛋-Opioid Receptors May Mediate the Protective Effect of Testosterone on the Development of Temporomandibular Joint Nociception in Male Rats

Aims: To investigate whether the protective effect of testosterone on the development of temporomandibular joint (TMJ) nociception in male rats is mediated by the activation of central opioid mechanisms. Methods: Experiments were performed on 156 male Wistar rats. A pharmacologic approach was used to assess the ability of opioid receptor antagonists infused into the dorsal portion of the brainstem and adjacent to the caudal component (subnucleus caudalis) of the spinal trigeminal nucleus to block the protective effect of testosterone in male rats. The TMJ injection of 0.5% formalin was used as a nociceptive stimulus. One-way or two-way ANOVA was used for data analyses. Results: The injection of 0.5% formalin into the TMJ induced a significant nociceptive behavior in gonadectomized male rats (P < .05), but not in naïve, sham, and testosterone-replaced gonadectomized rats, confirming that testosterone prevents the development of TMJ nociception. The injection of either the nonselective opioid receptor antagonist naloxone (15 µg) or the simultaneous injection of the µ-opioid receptor antagonist Cys2, Tyr3, Orn5, Pen7amide (CTOP, 30 µg) and the κ-opioid receptor antagonist Nor-Binaltorphimine (Nor-BNI, 90 µg) significantly increased the 0.5% formalin-induced behavioral response in sham and testosterone-replaced gonadectomized rats (P < .05) but had no effect in gonadectomized rats. However, the injection of each selective opioid receptor antagonist alone or the simultaneous injection of μ- or κ- and δ-opioid receptor antagonists had no effect. Conclusion: These findings indicate that the protective effect of endogenous testosterone on the development of TMJ nociception in male rats is mediated by the activation of central opioid mechanisms. Furthermore, the coactivation of central μ- and κ-opioid receptors is necessary for testosterone to protect male rats from developing TMJ nociception.

nociception; opioid receptors; pain; temporomandibular joint; testosterone

1. Cooper BC, Kleinberg I. Examination of a large patient population for the presence of symptoms and signs of temporomandibular disorders. Cranio 2007;25:114–126.

2. LeResche L. Epidemiology of temporomandibular disorders: Implications for the investigation of etiologic factors. Crit Rev Oral Biol Med 1997;8:291–305.

3. Carlsson G, LeResche L. Epidemiology of temporomandibular disorders. In: Sessle BJ, Bryant P, Dionne R (eds). Progress in Pain Research and Management. Seattle: IASP Press 1995; 211–226.

4. Fischer L, Clemente JT, Tambeli CH. The protective role of testosterone in the development of temporomandibular joint pain. J Pain 2007;8:437–442.

5. Fischer L, Arthuri MT, Torres-Chávez KE, Tambeli CH. Contribution of endogenous opioids to gonadal hormones-induced temporomandibular joint antinociception. Behav Neurosci 2009;123:1129–1140.

6. Zimmermann M. Ethical guidelines for investigations of experimental pain in conscious animals. Pain 1983;16:109–110.

7. Danzebrink RM, Green SA, Gebhart GF. Spinal mu and delta, but not kappa, opioid-receptor agonists attenuate responses to noxious colorectal distension in the rat. Pain 1995;63:39–47.

8. Tambeli CH, Quang P, Levine JD, Gear RW. Contribution of spinal inhibitory receptors in heterosegmental antinociception induced by noxious stimulation. Eur J Neurosci 2003;18:2999–3006.

9. Fischer L, Parada CA, Tambeli CH. A novel method for subarachnoid drug delivery in the medullary region of rats. J Neurosci Methods 2005;148:108–112.

10. Fischer L, Torres-Chávez KE, Clemente-Napimoga JT, et al. The influence of sex and ovarian hormones on temporomandibular joint nociception in rats. J Pain 2008;9:630–638.

11. Gordon FT, Soliman MR. Diurnal variation in the acute effects of estradiol and progesterone on beta-endorphin and metenkephalin levels in specific brain regions of ovariectomized rats. Pharmacology 1994;49:192–198.

12. Liu J, Tsang S, Wong TM. Testosterone is required for delayed cardioprotection and enhanced heat shock protein 70 expression induced by preconditioning. Endocrinology 2006;147:4569–4577.

13. Banu SK, Govindarajulu P, Aruldhas MM. Testosterone and estradiol up-regulate androgen and estrogen receptors in immature and adult rat thyroid glands in vivo. Steroids 2002; 67:1007–1014.

14. Horan P, Taylor J, Yamamura HI, Porreca F. Extremely long-lasting antagonistic actions of nor-binaltorphimine (nor-BNI) in the mouse tail-flick test. J Pharmacol Exp Ther 1992;260: 1237–1243.

15. Wettstein JG, Grouhel A. Opioid antagonist profile of SC nor-binaltorphimine in the formalin paw assay. Pharmacol Biochem Behav 1996;53:411–416.

16. Roveroni RC, Parada CA, Cecilia M, Veiga FA, Tambeli CH. Development of a behavioral model of TMJ pain in rats: The TMJ formalin test. Pain 2001;94:185–191.

17. Rosland JH. The formalin test in mice: The influence of ambient temperature. Pain 1991;45:211–216.

18. Morales AJ, Nolan JJ, Nelson JC, Yen SS. Effects of replacement dose of dehydroepiandrosterone in men and women of advancing age. J Clin Endocrinol Metab 1994;78:1360–1367.

19. Pluchino N, Ninni F, Casarosa E, et al. Sex differences in brain and plasma beta-endorphin content following testosterone, dihydrotestosterone and estradiol administration to gonadectomized rats. Neuroendocrinology 2009;89:411–423.

20. Liu NJ, Chakrabarti S, Schnell S, Wessendorf M, Gintzler AR. Spinal synthesis of estrogen and concomitant signaling by membrane estrogen receptors regulate spinal κ- and μ-opioid receptor heterodimerization and female-specific spinal morphine antinociception. J Neurosci 2011;31:11836–11845.

21. Johansson P, Ray A, Zhou Q, Huang W, Karlsson K, Nyberg F. Anabolic androgenic steroids increase beta-endorphin levels in the ventral tegmental area in the male rat brain. Neurosci Res 1997;27:185–189.

22. Dubner R, Bennett GJ. Spinal trigeminal mechanisms of nociception. Annu Rev Neurosci 1983;6:381–418.

23. Sessle BJ. Acute and chronic craniofacial pain: Brainstem mechanisms of nociceptive transmission and neuroplasticity, and their clinical correlates. Crit Rev Oral Biol Med 2000;1:57–91.

24. Atweh SF, Kuhar MJ. Autoradiographic localization of opiate receptors in rat brain. I. Spinal cord and lower medulla. Brain Res 1977;124:53–67.

25. Mitchell JL, Silverman MB, Aicher SA. Rat trigeminal lamina I neurons that project to thalamic or parabrachial nuclei contain the mu-opioid receptor. Neuroscience 2004;128:571–582.

26. Besse D, Lombard MC, Zajac JM, Roques BP, Besson JM. Pre- and postsynaptic distribution of mu, delta and kappa opioid receptors in the superficial layers of the cervical dorsal horn of the rat spinal cord. Brain Res 1990;521:15–22.

27. Arvidsson U, Riedl M, Chakrabarti S, et al. The kappa-opioid receptor is primarily postsynaptic: Combined immunohistochemical localization of the receptor and endogenous opioids. Proc Natl Acad Sci USA 1995;92:5062–5066.

28. Arvidsson U, Riedl M, Chakrabarti S, et al. Distribution and targeting of a mu-opioid receptor (MOR1) in brain and spinal cord. J Neurosci 1995;15:3328–3341.